Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

2017 ◽  
Vol 5 (11) ◽  
pp. 891-902 ◽  
Author(s):  
Myung-Ju Ahn ◽  
Dong-Wan Kim ◽  
Byoung Chul Cho ◽  
Sang-We Kim ◽  
Jong Seok Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Dose Escalation ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cns Metastases ◽  
Open Label ◽  
Label Dose ◽  
Egfr Mutant

scholarly journals Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

2016 ◽  
Vol 17 (7) ◽  
pp. 883-895 ◽  
Author(s):  
Scott J Antonia ◽  
José A López-Martin ◽  
Johanna Bendell ◽  
Patrick A Ott ◽  
Matthew Taylor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

2019 ◽  
Vol 7 (4) ◽  
pp. 347-357 ◽  
Author(s):  
Natasha B Leighl ◽  
Matthew D Hellmann ◽  
Rina Hui ◽  
Enric Carcereny ◽  
Enriqueta Felip ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 1 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document